Clinical Research Directory

Inclusion Criteria: * Men aged 18 and older with histologically confirmed prostate cancer after prostatectomy with detectable PSA. PSA does not need to be detectable for men with pathologically node positive disease. * KPS \>=70 * Patient with no evidence of distant metastatic disease on PET/CT/MRI or bone scan \< 9 months prior to enrollment. Patients with positive pelvic lymph nodes are eligible. * Ability to receive MRI-guided radiotherapy. * Equivocal evidence of metastatic disease outside the pelvis on standard imaging requires documented negative biopsy. * Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Exclusion Criteria: * Prior history of receiving pelvic radiotherapy. * Patient with inflammatory bowel disease. * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of ultra-hypofractionated radiotherapy. * History of bladder neck or urethral stricture.